Cover Image
市場調查報告書

Dravet症候群 (小兒重度肌痙攣癲癇症候群) :開發中產品分析

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 361625
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
Dravet症候群 (小兒重度肌痙攣癲癇症候群) :開發中產品分析 Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 72 Pages
簡介

本報告提供Dravet症候群 (小兒重度肌痙攣癲癇症候群) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

Dravet症候群 (小兒重度肌痙攣癲癇症候群)的概要

治療藥的開發

  • 開發中產品的概要

Dravet症候群 (小兒重度肌痙攣癲癇症候群):企業開發中的治療藥

Dravet症候群 (小兒重度肌痙攣癲癇症候群):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

Dravet症候群 (小兒重度肌痙攣癲癇症候群):企業開發中的產品

Dravet症候群 (小兒重度肌痙攣癲癇症候群)的治療藥開發企業

  • Biscayne Pharmaceuticals, Inc.
  • GW Pharmaceuticals Plc
  • INSYS Therapeutics, Inc.
  • OPKO Health, Inc.
  • PTC Therapeutics, Inc.
  • Sage Therapeutics, Inc.
  • Xenon Pharmaceuticals Inc.
  • Zogenix, Inc.

Dravet症候群 (小兒重度肌痙攣癲癇症候群):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

Dravet症候群 (小兒重度肌痙攣癲癇症候群):最近的開發平台趨勢

Dravet症候群 (小兒重度肌痙攣癲癇症候群):暫停中的計劃

Dravet症候群 (小兒重度肌痙攣癲癇症候群):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8123IDB

Summary

Global Markets Direct's, ‘Lennox-Gastaut Syndrome - Pipeline Review, H1 2016', provides an overview of the Lennox-Gastaut Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome
  • The report reviews pipeline therapeutics for Lennox-Gastaut Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lennox-Gastaut Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Lennox-Gastaut Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lennox-Gastaut Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Overview
  • Therapeutics Development
    • Pipeline Products for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Overview
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics under Development by Companies
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Products under Development by Companies
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Companies Involved in Therapeutics Development
    • Biscayne Pharmaceuticals, Inc.
    • GW Pharmaceuticals Plc
    • INSYS Therapeutics, Inc.
    • OPKO Health, Inc.
    • PTC Therapeutics, Inc.
    • Sage Therapeutics, Inc.
    • Xenon Pharmaceuticals Inc.
    • Zogenix, Inc.
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ataluren - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIS-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cannabidiol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CUR-1916 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fenfluramine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide for Dravet Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAGE-217 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Recent Pipeline Updates
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Product Development Milestones
    • Featured News & Press Releases
      • May 05, 2016: Zogenix Announces ZX008 New Efficacy and Safety Data for Treatment of Seizures in Dravet Syndrome
      • Apr 21, 2016: New Data on Zogenix ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
      • Mar 14, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex (cannabidiol)
      • Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals
      • Jan 19, 2016: Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
      • Jan 11, 2016: Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
      • Dec 14, 2015: Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome
      • Dec 07, 2015: Biscayne Pharmaceuticals Presents Data At 2015 AES Meeting Confirming BIS-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug
      • Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
      • Dec 07, 2015: Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by INSYS Therapeutics, Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by OPKO Health, Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by PTC Therapeutics, Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Sage Therapeutics, Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Xenon Pharmaceuticals Inc., H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline by Zogenix, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Therapeutics - Recent Pipeline Updates, H1 2016
  • Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top